Relmada Therapeutics, Inc
Relmada Therapeutics, Inc is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc is a company.
Key people at Relmada Therapeutics, Inc.
Key people at Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biotechnology company dedicated to developing innovative therapies for central nervous system (CNS) disorders, oncology, and related conditions with high unmet needs.[1][2][4] Its lead candidates include NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel in Phase 2 for non-muscle invasive bladder cancer (NMIBC), and sepranolone, a Phase 2b-ready neurosteroid for Prader-Willi Syndrome, Tourette syndrome, and other compulsivity disorders like OCD.[2][4][5] Previously focused on esmethadone (REL-1017), an NMDA receptor antagonist for depression, the company has pivoted to these programs while evaluating new acquisitions to maximize shareholder value.[1][2][3] NDV-01 targets BCG-unresponsive NMIBC patients, showing strong complete response rates (e.g., 91% anytime in trials), with convenient in-office administration under 10 minutes without anesthesia.[4][5] Sepranolone modulates GABA-A receptors to address excess GABAergic activity, backed by safety data from over 335 patients.[4] Headquartered in Coral Gables, Florida, Relmada serves patients with CNS and oncology challenges through novel formulations that enhance efficacy and reduce toxicity.[2]
Founded in 2004, Relmada Therapeutics began as a biotech firm exploring novel chemical entities and reformulations of existing drugs to treat CNS disorders.[2] Early efforts centered on candidates like esmethadone (d-methadone, REL-1017), an NMDA channel blocker for depression and other CNS indications, alongside programs such as REL-1015 (LevoCap ER for pain) and others.[1][3] The company evolved through strategic shifts, pivoting from a heavy CNS focus—including sepranolone for Tourette syndrome—to its current emphasis on oncology with NDV-01's Phase 2 advancement in NMIBC and sepranolone's readiness for Prader-Willi trials.[2][4][5] Key milestones include positive Q3 2025 data for NDV-01 in BCG-unresponsive patients and ongoing presentations at events like the Society of Urologic Oncology (Dec 2025) and AUA meetings.[2][4] Leadership features experts like CEO with urology focus, supported by a scientific advisory board from Harvard, Memorial Sloan Kettering, MD Anderson, and others, driving translational research in bladder cancer and intravesical therapies.[8]
Relmada rides the wave of precision oncology and neurosteroid therapies amid rising demand for bladder-sparing NMIBC treatments post-BCG shortages and failures, where standard therapies fall short.[4][5] Timing aligns with advancing intravesical innovations and GABA modulation for rare CNS disorders like Prader-Willi, fueled by market forces such as aging populations driving bladder cancer incidence and unmet needs in compulsivity beyond SSRIs.[2][4] In biotech, Relmada influences the ecosystem by pioneering abuse-deterrent reformulations and NCEs (new chemical entities), contributing to sustained-release tech that reduces treatment burden—echoed in its advisory ties to top institutions shaping guidelines for hematuria, TURBT, and immunotherapy.[1][8] This positions it amid broader shifts toward office-based, non-invasive cancer care and targeted CNS interventions.
Relmada's near-term catalysts include NDV-01 Phase 2 readouts, sepranolone Phase 2b initiation in Prader-Willi, and 2025 conference data, potentially driving partnerships or pivotal trials.[2][4] Trends like AI-optimized formulations, immunotherapy combos for NMIBC, and expanded GABA therapies for OCD/Tourette will shape its path, with pipeline acquisitions accelerating growth.[2] Influence may evolve from CNS pioneer to oncology contender, leveraging its Miami hub and expert network for value inflection—watch for Q4 2025 updates to gauge momentum toward commercialization.[2][4] This builds on its biotech resilience, transforming unmet needs into accessible innovations.
